Abiomed announces new data from the USpella IRB registry of Impella 2.

Abiomed announces new data from the USpella IRB registry of Impella 2.5 patients Abiomed Inc generic cialis . , a respected provider of breakthrough heart support technologies, announced brand-new clinical data from USpella today, the 1st U.S. Multicenter registry of Impella 2.5 sufferers analyzing the safety and feasibility of remaining ventricular support with the Impella 2.5 during high-risk percutaneous coronary intervention and treatment of acute myocardial infarction . USpella, presented at TCT 2009 by Brijeshwar Maini, M.D., co-chair, cardiovascular research, interventional cardiologist, Pinnacle Health; attending cardiologist, Moffitt Center & Vascular Group, evaluated data from 16 Impella 2.5 centers with IRB approval and over 181 individuals from the more than 1,000 reported commercial Impella 2.5 cases.